Teva faces backlash over acquisitions
Consumer advocates concerned about the impact of consolidation in the generic drug industry on prices and supply have not been mollified by pharmaceutical giant Teva’s sudden decision to drop its bid...To view the full article, register now.
Already a subscriber? Click here to view full article